Inventor
SNOECK VEERLE
BE22 patents
⚠️ This page may combine multiple inventors who share the name “SNOECK VEERLE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABLYNX NV
12 patentsUS10858418B2Dec 8, 2020
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV18 citations93
US11009511B2May 18, 2021
Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
ABLYNX NV6 citations84
US11192937B2Dec 7, 2021
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV5 citations83
US11192938B2Dec 7, 2021
Serum albumin binding proteins containing immunoglobulin single variable domains
ABLYNX NV5 citations83
US12516105B2Jan 6, 2026
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV1 citations74
US12006352B2Jun 11, 2024
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV1 citations72
US11644471B2May 9, 2023
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV2 citations72
US12553901B2Feb 17, 2026
Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
ABLYNX NV1 citations64
US11466089B2Oct 11, 2022
Chemokine receptor binding polypeptides
ABLYNX NV0 citations61
US11919966B2Mar 5, 2024
Methods for inhibiting tumor growth or treating cancer by administering an immunoglobulin single variable domain that binds glucocorticoid-induced TNFR family-related receptor (GITR)
ABLYNX NV0 citations54
US11059899B1Jul 13, 2021
Polypeptides that bind glucocorticoid-induced TNFR family-related receptor (GITR)
ABLYNX NV1 citations54
US12480957B2Nov 25, 2025
Method of screening for anti-drug antibodies against immunoglobulin single variable domain-based drugs
ABLYNX NV0 citations47
INTREXON ACTOBIOTICS NV
5 patentsUS9539291B2Jan 10, 2017
Induction of mucosal tolerance to antigens
INTREXON ACTOBIOTICS NV2 citations72
US10668136B2Jun 2, 2020
Treatment of immune disease by mucosal delivery of antigens using genetically modified Lactococcus
INTREXON ACTOBIOTICS NV0 citations51
US10195269B2Feb 5, 2019
Induction of mucosal tolerance to antigens
INTREXON ACTOBIOTICS NV0 citations51
US10143729B2Dec 4, 2018
Treatment of immune disease by mucosal delivery of antigens using genetically modified Lactococcus
INTREXON ACTOBIOTICS NV0 citations51
US9526750B2Dec 27, 2016
Induction of mucosal tolerance to antigens
INTREXON ACTOBIOTICS NV0 citations51